CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 6 incoming connections
- ScaleMarket cap is $3.36B, above the global median of $1.18B
- FinancialsHigh structural barrier to entry
- Interpretations10 currently firing — 10
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.04%Above 5Y avg (0.70%)
Annual Rate
INR 20.00Paid quarterly
Payout Ratio
43.2%Sustainable
Last Ex-Dividend
Jul 30, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
321.32BINR3.36B · vs all stocks (USD)
Trailing P/E
59.18xvs Diagnostics & Research peers
Revenue (TTM)
28.91BINR302.41M · vs all stocks (USD)
Profit Margin
18.75%vs Diagnostics & Research peers
Beta
0.1880xvs all stocks
52-Week Change
16.47%vs all stocks
Forward Annual Dividend Yield
1.04%vs all stocks
Market Capitalization
321.32BINR3.36B · vs all stocks (USD)
Enterprise Value
309.68BINR3.24B · vs all stocks (USD)
Trailing P/E
59.18xvs Diagnostics & Research peers
Forward P/E
44.10xvs Diagnostics & Research peers
PEG Ratio
2.13xPrice to Sales (TTM)
11.09xvs Diagnostics & Research peers
Price to Book (MRQ)
12.78xvs Diagnostics & Research peers
Enterprise to Revenue
10.71xvs Diagnostics & Research peers
Enterprise to EBITDA
39.20xvs Diagnostics & Research peers
Gross Margin
66.47%vs Diagnostics & Research peers
Profit Margin
18.75%vs Diagnostics & Research peers
Operating Margin
25.46%vs Diagnostics & Research peers
Return on Assets (TTM)
16.05%vs Diagnostics & Research peers
Return on Equity (TTM)
19.86%vs Diagnostics & Research peers
Revenue (TTM)
28.91BINR302.41M · vs all stocks (USD)
Revenue per Share (TTM)
173.13INRUpdated Sep 23, 2026Quarterly Revenue Growth
19.10%vs Diagnostics & Research peers
Gross Profit (TTM)
17.40BINR182.06M · vs all stocks (USD)
EBITDA (TTM)
8.57BINR89.63M · vs all stocks (USD)
Net Income (TTM)
5.42BINR56.69M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
28.00%vs Diagnostics & Research peers
Operating Cash Flow (TTM)
6.36BINR66.49M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
5.05BINR52.80M · vs all stocks (USD)
Forward Annual Dividend Rate
20.00INRUpdated Sep 23, 2026Forward Annual Dividend Yield
1.04%vs all stocks
Trailing Annual Dividend Rate
16.00INRUpdated Sep 23, 2026Trailing Annual Dividend Yield
0.83%vs all stocks
5-Year Average Dividend Yield
0.70%vs all stocks
Payout Ratio
43.21%vs Diagnostics & Research peers
Minority Interest (Equity)
331.44MINRFY2026 · Mar 31, 2026Revenue
27.63BINRFY2026 · Mar 31, 2026Cost of Goods Sold
5.35BINRFY2026 · Mar 31, 2026Gross Profit
22.28BINRFY2026 · Mar 31, 2026Operating Income
10.25BINR107.22M · vs all stocks (USD)
Pre-tax Income
6.69BINRFY2026 · Mar 31, 2026Income Tax Expense
1.59BINRFY2026 · Mar 31, 2026Net Income
5.10BINRFY2026 · Mar 31, 2026EBIT
6.92BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
8.57BINRFY2026 · Mar 31, 2026Selling, General & Administrative
2.75BINRFY2026 · Mar 31, 2026Other Operating Expenses
2.30BINRFY2026 · Mar 31, 2026Non-operating Interest Income
670.12MINRFY2026 · Mar 31, 2026Non-operating Interest Expense
228.00MINRFY2026 · Mar 31, 2026EPS (Basic)
30.24INRFY2026 · Mar 31, 2026EPS (Diluted)
30.20INRFY2026 · Mar 31, 2026Basic Shares Outstanding
166.91MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
166.91MSharesFY2026 · Mar 31, 2026Net Income from Continuing Operations
5.10BINRFY2026 · Mar 31, 2026Minority Interests (P&L)
-49.75MINRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
4.53BINRFY2026 · Mar 31, 2026Free Cash Flow
2.86BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
2.43BINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
5.10BINRFY2026 · Mar 31, 2026Stock-based Compensation
237.76MINRFY2026 · Mar 31, 2026Other Non-cash Items
-479.75MINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-276.07MINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-53.23MINRFY2026 · Mar 31, 2026Capital Expenditures
-1.66BINRFY2026 · Mar 31, 2026Net Intangibles (CF)
-63.63MINRFY2026 · Mar 31, 2026Purchase of Investments
-15.16BINRFY2026 · Mar 31, 2026Sale of Investments
11.97BINRFY2026 · Mar 31, 2026Other Investing Activity
34.21MINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-4.82BINRFY2026 · Mar 31, 2026Long-term Debt Payments
0.00INRFY2026 · Mar 31, 2026Common Dividends Paid
-2.23BINRFY2026 · Mar 31, 2026Net Financing Cash Flow
-2.04BINRFY2026 · Mar 31, 2026Shares Outstanding
166.98MSharesUpdated Sep 23, 2026Float Shares
75.71MSharesUpdated Sep 23, 2026% Held by Insiders
54.71%vs all stocks
% Held by Institutions
33.21%vs all stocks
Total Cash (MRQ)
13.31BINR139.21M · vs all stocks (USD)
Total Cash per Share (MRQ)
79.70INRUpdated Sep 23, 2026Total Debt (MRQ)
1.99BINR20.82M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0783xvs Diagnostics & Research peers
Current Ratio (MRQ)
3.48xvs Diagnostics & Research peers
Book Value per Share (MRQ)
150.21INRUpdated Sep 23, 2026Total Assets
31.46BINR329.10M · vs all stocks (USD)
Total Current Assets
15.66BINRFY2026 · Mar 31, 2026Total Liabilities
6.05BINRFY2026 · Mar 31, 2026Total Non-current Assets
15.80BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
1.54BINRFY2026 · Mar 31, 2026Total Current Liabilities
4.51BINRFY2026 · Mar 31, 2026Cash
248.49MINRFY2026 · Mar 31, 2026Cash Equivalents
2.18BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
2.43BINRFY2026 · Mar 31, 2026Other Short-term Investments
10.88BINRFY2026 · Mar 31, 2026Accounts Receivable
1.11BINRFY2026 · Mar 31, 2026Inventory
438.55MINRFY2026 · Mar 31, 2026Accounts Payable
1.81BINRFY2026 · Mar 31, 2026Short-term Debt
535.74MINRFY2026 · Mar 31, 2026Long-term Debt
1.45BINRFY2026 · Mar 31, 2026Common Stock (Book)
1.68BINRFY2026 · Mar 31, 2026Retained Earnings
21.53BINRFY2026 · Mar 31, 2026Total Shareholders' Equity
25.41BINR265.84M · vs all stocks (USD)
Treasury Stock
420.35MINRFY2026 · Mar 31, 202652-Week Low
1.27KINRUpdated Sep 23, 202652-Week High
2.04KINRUpdated Sep 23, 202652-Week Change
16.47%vs all stocks
Beta
0.1880xvs all stocks
50-Day MA
1.87KINRUpdated Sep 23, 2026200-Day MA
1.57KINRUpdated Sep 23, 2026Avg 10-Day Volume
353.24KSharesUpdated Sep 23, 2026Avg 30-Day Volume
247.53KSharesUpdated Sep 23, 2026Diluted EPS (TTM)
32.44INRUpdated Sep 23, 202610 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 0.50
Supply Chain
Midstream position: 6 outgoing, 6 incoming connectionsNotable
Outgoing: 6.00Incoming: 6.00
High connectivity hub: 12 industry connectionsNotable
Total Connections: 12.00
Scale
Market cap is $3.36B, above the global median of $1.18BNotable
Market cap (USD): 3,361,279,759.783Global Median: 1,180,223,658.953
Levered free cash flow is $52.8M, above the global median of $18.73MNotable
Levered free cash flow (USD): 52,804,931.19Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
K+S Aktiengesellschaft
Tier 1ProductionThroughput-Bound ConversionFlowRule
Hyundai Steel Co.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Krishna Institute of Medical Sciences Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Genius Electronic Optical Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlow
Mueller Water Products Inc.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Medicover AB
Tier 1ProductionThroughput-Bound ConversionRuleFlow
JA Solar Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Zhuhai Bojay Electronics Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Luxi Chemical Group Co. Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Kehua Data Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
NVIDIA Corporation
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityROE, ROA, And Operating ROA ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year FCF With Growth And Margin
United States Lime & Minerals Inc.
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityROE, ROA, And Operating ROA ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year FCF With Growth And Margin
Catalyst Pharmaceuticals Inc.
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityROE, ROA, And Operating ROA ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year FCF With Growth And Margin